ICB therapy, which aims to reinvigorate T cells, has profoundly shifted the paradigm for advanced HCC treatment in the past few years.2 ICB therapy primarily functions to activate cytotoxic CD8+ T cells whose activity is repressed in the tumor microenvironment (TME). The gene discussed is CD8A; the disease is neoplasm.